KPC Pharmaceuticals Overview

  • Year Founded
  • 1951

Year Founded

  • Status
  • Public

  • Employees
  • 5,051

Employees

  • Stock Symbol
  • 600422

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $3.14
  • (As of Friday Closing)

KPC Pharmaceuticals General Information

Description

KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.

Contact Information

Website
www.kpc.com.cn
Formerly Known As
Kunming Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
SHG
Corporate Office
  • No. 166 Keyi Road
  • State New and High Technology Development Zone
  • Kunming, Yunnan 650106
  • China
+86 0871 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KPC Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.14 $3.16 $2.08 - $3.69 $2.37B 757M 9.1M $0.08

KPC Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 2,109,479 2,139,723 1,502,145 1,253,949
Revenue 1,069,249 1,088,799 1,229,789 1,278,214
EBITDA 77,112 109,793 107,023 130,589
Net Income 60,463 62,853 56,898 78,622
Total Assets 1,380,046 1,349,404 1,367,089 1,395,165
Total Debt 125,874 127,049 165,177 129,900
Public Fundamental Data provided by Morningstar, Inc. disclaimer

KPC Pharmaceuticals Patents

KPC Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2016503077-A Cyclodextrin carrier-based arteannuin compound complex and preparation method thereof Pending 14-Dec-2012 0000000000 0
JP-2016503078-A Arteannuin-cyclodextrin conjugate and method for producing the same Active 14-Dec-2012 0000000000 0
JP-2016500116-A Use of artemether in the preparation of a drug to treat leukemia Pending 29-Nov-2012 000000000 0
EP-2292241-A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof Inactive 22-May-2008 00000000000
EP-2292241-A4 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof Inactive 22-May-2008 A61K31/7048
To view KPC Pharmaceuticals’s complete patent history, request access »

KPC Pharmaceuticals Executive Team (5)

Name Title Board Seat Contact Info
Zhong Xianggang President
Wang Shaoquan Chief Financial Officer
You’re viewing 2 of 5 executive team members. Get the full list »

KPC Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KPC Pharmaceuticals Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Leads Biolabs 29-Oct-2020 00000 0000 000.00 Biotechnology
Shenogen 29-Jul-2016 00000 0000 0000 Drug Discovery
Rani Therapeutics 08-Mar-2016 00000 0000 000.00 Drug Delivery
ChengYiSheng 27-Jan-2016 00000 0000 00.000 Application Software
E-Young 28-Dec-2015 Seed Round Educational Software
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

KPC Pharmaceuticals Subsidiaries (1)

Company Name Industry Location Founded
Hunan Djwk Medical Logistics Changsha, China 0000
To view KPC Pharmaceuticals’s complete subsidiaries history, request access »

KPC Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated December, 01, 2023

33.29 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 456

Rank

00.00

Percentile

To view KPC Pharmaceuticals’s complete esg history, request access »

KPC Pharmaceuticals Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
Rani Therapeutics 08-Mar-2016 00000 00000 00 000.00 Completed
  • 12 buyers
ChengYiSheng 27-Jan-2016 00000 00000 00 00.000 Completed
  • 2 buyers
Rani Therapeutics 16-Jul-2015 Later Stage VC 000.00 Completed
  • 14 buyers
To view KPC Pharmaceuticals’s complete exits history, request access »

KPC Pharmaceuticals FAQs

  • When was KPC Pharmaceuticals founded?

    KPC Pharmaceuticals was founded in 1951.

  • Where is KPC Pharmaceuticals headquartered?

    KPC Pharmaceuticals is headquartered in Kunming, China.

  • What is the size of KPC Pharmaceuticals?

    KPC Pharmaceuticals has 5,051 total employees.

  • What industry is KPC Pharmaceuticals in?

    KPC Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is KPC Pharmaceuticals a private or public company?

    KPC Pharmaceuticals is a Public company.

  • What is KPC Pharmaceuticals’s stock symbol?

    The ticker symbol for KPC Pharmaceuticals is 600422.

  • What is the current stock price of KPC Pharmaceuticals?

    As of 17-May-2024 the stock price of KPC Pharmaceuticals is $3.14.

  • What is the current market cap of KPC Pharmaceuticals?

    The current market capitalization of KPC Pharmaceuticals is $2.37B.

  • What is KPC Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for KPC Pharmaceuticals is $1.07B.

  • What is KPC Pharmaceuticals’s annual earnings per share (EPS)?

    KPC Pharmaceuticals’s EPS for 12 months was $0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »